Loading viewer...
investor_presentation
Format: PDF investor_presentation
HY 2024 Results UCB on Growth Path for a Decade+ Capital Market Earnings Call 25 July 2024Our Purpose: Create value for patients, now and into the future
Capital Market Earnings Call
25 July 2024Our Purpose:
Create value for patients, now and into the futureProprietary and Confidential Property of UCBProprietary and Confidential Property of UCB
2Disclaimer & Safe harbor
This document contains forward- looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”,
“estimates”, “may”, “will”, “continue” and similar expressions. These forward- looking statements are based on current plans, estimates and beliefs of management . All statements, other than
statements of historical facts, are statements that could be deemed forward -looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial
information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward- looking statements are not guaranteeing
future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or
industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward- looking statements contained in this document .
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive
conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the
prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues ; potential
or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates,
competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring
and retention of its employees . There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and
approved . Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans . So far, the complexity of the human
Preview truncated — download the full document for the complete content.
investor_presentation
26 Pages
Fusion Pharmaceuticals